Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
380 stopped studies mapped to Malignant Uterine Neoplasm and descendants · 86% state a reason
Over the 380 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04424641 | A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid… | Phase 1 / Phase 2 | terminated | Jun 11, 2020 | Genmab | Study was terminated due to MTD was reached | Other (stated, no rule matched) |
| NCT05584332 | A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV… | Phase 3 | terminated | Oct 18, 2022 | Shanghai Bovax Biotechnology Co., Ltd. | Strategic adjustment | Sponsor / business decision |
| NCT00298064 | Assessment of EGFR Genomic Alterations as Prognostic Markers in Cervical Cancer | N/A | withdrawn | Mar 1, 2006 | University of New Mexico | not stated | Not stated |
| NCT05614453 | Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer…(ITTACC) | Phase 2 | withdrawn | Nov 14, 2022 | Australia New Zealand Gynaecological Oncology Group | BeiGene has withdrawn their support owing to sitravatinib supply concerns. Mirati is ceasing… | Drug supply |
| NCT01992861 | MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA… | — | terminated | Nov 25, 2013 | University of Washington | not stated | Not stated |
| NCT03824704 | A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected… | Phase 2 | terminated | Jan 31, 2019 | pharmaand GmbH | Sponsor made a business decision to discontinue the study due to low accrual. | Enrollment / accrual |
| NCT03400943 | Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3) | Phase 3 | terminated | Jan 17, 2018 | Bayer | Due to a change in the development program, the study was closed prematurely. | Other (stated, no rule matched) |
| NCT04073485 | Microwave Ablation for Uterine Fibroids | N/A | terminated | Aug 29, 2019 | Chinese University of Hong Kong | poor patient accrual | Enrollment / accrual |
| NCT03642990 | NR in Chemo-induced Peripheral Neuropathy | Phase 2 | terminated | Aug 22, 2018 | Donna Hammond, PhD | Enrollment challenges | Enrollment / accrual |
| NCT02291055 | A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human… | Phase 1 / Phase 2 | terminated | Nov 14, 2014 | Advaxis, Inc. | not stated | Not stated |
| NCT02853604 | Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical Cancer(AIM2CERV) | Phase 3 | terminated | Aug 3, 2016 | Advaxis, Inc. | not stated | Not stated |
| NCT05419817 | Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors… | Phase 2 | withdrawn | Jun 15, 2022 | Haider Mahdi | Slow Accrual | Enrollment / accrual |
| NCT05506800 | Guangzhou Women's Health Cohort Study (GWHCS) | — | suspended | Aug 18, 2022 | Guangzhou Women and Children's Medical Center | Due to the rebound of the COVID-19 epidemic in the city, we have to suspend the project temporarily. | COVID-19 / pandemic |
| NCT02393248 | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies -… | Phase 1 / Phase 2 | terminated | Mar 19, 2015 | Incyte Corporation | not stated | Not stated |
| NCT05393635 | ITIL-168 in Advanced Solid Tumors(DELTA-2) | Phase 1 | withdrawn | May 26, 2022 | Instil Bio | business decision | Sponsor / business decision |
| NCT04672980 | RTX-321 Monotherapy in Patients With HPV 16+ Tumors | Phase 1 | terminated | Dec 17, 2020 | Rubius Therapeutics | The Sponsor terminated study after dosing 3 dose groups (9 pts) and closed trial on 11/30/22.… | Other (stated, no rule matched) |
| NCT04294836 | Curcumin in Advanced Cervical Cancer | Phase 2 | withdrawn | Mar 4, 2020 | Instituto Nacional de Cancerologia, Columbia | Issues with local regulatory authority | Other (stated, no rule matched) |
| NCT04762225 | RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors… | Phase 1 | terminated | Feb 21, 2021 | Repertoire Immune Medicines | Development program terminated | Other (stated, no rule matched) |
| NCT05061940 | This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status… | — | terminated | Sep 30, 2021 | Repertoire Immune Medicines | Development program terminated | Other (stated, no rule matched) |
| NCT03693846 | Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors | Phase 2 | terminated | Oct 3, 2018 | Abramson Cancer Center at Penn Medicine | Terminated due to slow enrollment and lack of efficacy | Efficacy / futility |
| NCT04368130 | SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer Care(SIGNAL) | N/A | withdrawn | Apr 29, 2020 | Dana-Farber Cancer Institute | The anomaly detection system is still under development and is not ready to test. | Other (stated, no rule matched) |
| NCT04943627 | Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical… | Phase 3 | withdrawn | Jun 29, 2021 | Agenus Inc. | Strategic Business Decision | Sponsor / business decision |
| NCT02601209 | Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or… | Phase 1 / Phase 2 | terminated | Nov 10, 2015 | National Cancer Institute (NCI) | Interim monitoring | Other (stated, no rule matched) |
| NCT02117817 | Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian… | Phase 1 | withdrawn | Apr 21, 2014 | Rutgers, The State University of New Jersey | Research cancelled | Other (stated, no rule matched) |
| NCT03400956 | Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4) | Phase 3 | terminated | Jan 17, 2018 | Bayer | Due to a change in the development program, the study was closed prematurely. | Other (stated, no rule matched) |
| NCT03834571 | Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and… | Phase 2 | withdrawn | Feb 8, 2019 | AIDS Malignancy Consortium | Not approved by CTEP | Other (stated, no rule matched) |
| NCT03077698 | An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer | Phase 2 | terminated | Mar 13, 2017 | Xenetic Biosciences, Inc. | The study was discontinued due to a change in development strategy and not due safety concern. | Safety / toxicity |
| NCT04230954 | Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical… | Phase 2 | terminated | Jan 18, 2020 | University of South Alabama | PI left institution | Investigator |
| NCT04178460 | A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid… | Phase 1 | terminated | Nov 26, 2019 | Zai Lab (Shanghai) Co., Ltd. | This termination decision is a business decision and is not due to any safety concerns. | Safety / toxicity |
| NCT04806945 | A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 +… | Phase 3 | withdrawn | Mar 19, 2021 | Shanghai Henlius Biotech | The sponsor terminated the trial. | Other (stated, no rule matched) |
| NCT03924245 | Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant… | Phase 1 | terminated | Apr 23, 2019 | Vanderbilt-Ingram Cancer Center | Change in participant landscape and other treatment availability | Other (stated, no rule matched) |
| NCT03977311 | MR-Guided High-Intensity Focused Ultrasound in Conjunction With Radiation Therapy for the… | N/A | withdrawn | Jun 6, 2019 | Washington University School of Medicine | PI decided not to go forward with study. | Other (stated, no rule matched) |
| NCT04611139 | Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers | Phase 1 | withdrawn | Nov 2, 2020 | HonorHealth Research Institute | Salarius discontinued support | Other (stated, no rule matched) |
| NCT03324958 | VIrtual REality Glasses for the Enhancement of Acute BRACHYtherapy Tolerance for…(Vire-Brachy) | N/A | terminated | Oct 30, 2017 | Centre Hospitalier Universitaire de Saint Etienne | Enrollment difficulties | Enrollment / accrual |
| NCT01285102 | Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From… | Phase 1 | terminated | Jan 27, 2011 | Fox Chase Cancer Center | This study was closed early by the DSMB due to increased toxicity. | Safety / toxicity |
| NCT03945786 | Diagnostic Performance of Hybrid PET/MRI in the Staging of Endometrial Carcinoma | — | suspended | May 10, 2019 | Xuanwu Hospital, Beijing | Recuriting inclusion and exclusion criteria will be changed as COVID-19. | COVID-19 / pandemic |
| NCT00900562 | Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic… | Phase 2 | terminated | May 13, 2009 | PharmaMar | Slow and poor recruitment. | Enrollment / accrual |
| NCT03328013 | Impact of HPV Vaccination to Catch up in the Emergence of Lesions of the Cervix(HPVAC) | — | terminated | Nov 1, 2017 | University Hospital, Brest | manager's decision | Other (stated, no rule matched) |
| NCT01902966 | Feasibility - Beta Adrenergic Blockade (BB) in Cervical Cancer (CX) | N/A | terminated | Jul 18, 2013 | M.D. Anderson Cancer Center | low accrual and lack of funding | Enrollment / accrual |
| NCT04099277 | A Study of LY3435151 in Participants With Solid Tumors | Phase 1 | terminated | Sep 23, 2019 | Eli Lilly and Company | Study terminated due to strategic business decision by Eli Lilly and Company. | Sponsor / business decision |
| NCT02127151 | A Parp Inhibitor (BMN 673) for Inoperable Advanced eNDometrial cAncer(PANDA) | Phase 2 | withdrawn | Apr 30, 2014 | University College, London | Withdrawal of Industry support for the study | Other (stated, no rule matched) |
| NCT00911079 | Pilot Study of a Catheter-based Ultrasound Hyperthermia System | N/A | terminated | Jun 1, 2009 | University of California, San Francisco | Low Accrual | Enrollment / accrual |
| NCT00232713 | Uterine Fibroid Pregnancy Registry | — | terminated | Oct 5, 2005 | Syneos Health | not stated | Not stated |
| NCT00978874 | Fluorine F 18 EF5 PET/CT Imaging in Patients With Locally Advanced or… | N/A | terminated | Sep 17, 2009 | Abramson Cancer Center at Penn Medicine | The PI is no longer with our institution | Other (stated, no rule matched) |
| NCT00577317 | Flexitouch® Home Maintenance Therapy or Standard Home Maintenance Therapy in Treating… | Phase 3 | terminated | Dec 20, 2007 | Gynecologic Oncology Group | not stated | Not stated |
| NCT00582205 | Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and… | Phase 2 | terminated | Dec 28, 2007 | University of Oklahoma | Study completed per investigator. | Investigator |
| NCT03786107 | HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for… | — | terminated | Dec 24, 2018 | Puma Biotechnology, Inc. | The study was stopped early due to increased global access to genomic screening. It is no longer… | Other (stated, no rule matched) |
| NCT04498520 | Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic… | Phase 1 | withdrawn | Aug 4, 2020 | Pamela Munster | Funding | Funding |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in… | Phase 1 / Phase 2 | withdrawn | Jul 9, 2020 | NKGen Biotech, Inc. | Trial not initiated | Other (stated, no rule matched) |
| NCT01016561 | Magnetic Resonance Imaging-Based Radiation Therapy and Cisplatin in Patients With Stage… | N/A | terminated | Nov 19, 2009 | Abramson Cancer Center at Penn Medicine | Poor accrual/enrollments | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jul 25, 2023source: clinicaltrials